(E)-5,5-dimethyl-4-oxohex-2-enoic acid | 20972-41-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: (E)-5,5-dimethyl-4-oxohex-2-enoic acid
• 英文别名: 5,5-dimethyl-4-oxo-hex-2t-enoic acid；5,5-Dimethyl-4-oxo-hex-2t-ensaeure；5,5-dimethyl-4-oxo-2-hexenoic acid；trans-β-Pivaloyl-acrylsaeure；trans-3-Pivaloylacrylsaeure；(2E)-5,5-Dimethyl-4-oxohex-2-enoic acid
• CAS: 20972-41-2
• 化学式: C₈H₁₂O₃
• 分子量: 156.181
• InChiKey: KSSQYRKIMWTEME-SNAWJCMRSA-N

物化性质

• 熔点：
  62.85 °C
• 沸点：
  279.8±23.0 °C(Predicted)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-5,5-dimethyl-4-oxohex-2-enoic acid 以 乙醚 为溶剂， 生成 cis-3-Pivaloylacrylsaeure
  参考文献：
  名称：

  Synthesis of 6-t-alkyl-3-pyridazinones

  摘要：

  一类6-t-烷基-3-吡啶酮是通过使用强光照射和与肼反应从3-t-酰基-2-丙烯酸制备的。

  公开号：

  US04411753A1
• 作为产物：
  描述：

  methyl (E)-5,5-dimethyl-4-oxohex-2-enoate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 5.0h， 生成 (E)-5,5-dimethyl-4-oxohex-2-enoic acid
  参考文献：
  名称：

  Highly Selective Rhodium-Catalyzed Conjugate Addition Reactions of 4-Oxobutenamides

  摘要：

  [GRAPHICS]A variety of 4-oxobutenamides 1 were subjected to rhodium-catalyzed conjugate addition with arylboronic acids providing high regio- and enantioselectivity (97:3 to > 99:1, > 96% ee) and moderate to excellent yields (54-99%). The key to high selectivity is the use of sterically demanding P-chiral diphosphines, such as Tangphos or Duanphos. The product oxobutanamides 2 may be converted to alternate targets by selective derivatization of either the amide or ketone functional group. A stereochemical model predicting the absolute sense of induction was developed based on single-crystal X-ray structures of product and precatalyst.

  DOI：

  10.1021/jo701682c

文献信息

• PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Liu Chunjian

  公开号：US20070213300A1

  公开（公告）日：2007-09-13

  Compounds having the Formula (I), including pharmaceutically acceptable salts thereof, wherein at least one of X 1 , X 2 or X 3 is and any remaining X 1 , X 2 or X 3 is hydrogen, which are useful as kinase inhibitors, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A 1 , A 2 and m are as described herein.

  具有化学式（I）的化合物，包括其药学上可接受的盐，其中X1、X2或X3中至少有一个是氢，其余的X1、X2或X3是氢，这些化合物可用作激酶抑制剂，其中R1、R2、R3、R4、R5、R6、A1、A2和m如本文所述。
• 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors
  申请人：Broughton Barff Howard

  公开号：US20070225267A1

  公开（公告）日：2007-09-27

  The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.

  本发明提供了化学式（I）的BACE抑制剂；以及它们的使用和制备方法，以及用于它们制备的中间体。
• Hypervalent Iodine Reagents Enable Chemoselective Deboronative/Decarboxylative Alkenylation by Photoredox Catalysis
  作者：Hanchu Huang、Kunfang Jia、Yiyun Chen

  DOI：10.1002/anie.201410176

  日期：2015.2.2

  hypervalent‐iodine‐enabled radical decarboxylative alkenylation reaction, and a novel benziodoxole‐vinyl carboxylic acid reaction intermediate was isolated. This C(sp3)C(sp2) coupling reaction leads to aryl‐and acyl‐substituted alkenes containing various sensitive functional groups. The excellent chemoselectivity, stable reactants, and neutral aqueous reaction conditions of the reaction suggest future biomolecule

  化学选择性C（SP 3） C（SP 2）在温和的反应条件下偶联反应用于合成具有敏感的官能团的烷基取代烯烃是有用的。此处报道的是在室温下中性水反应条件下，通过脱硼/脱羧序列产生的可见光诱导的化学选择性烯基化。该反应代表了第一个高价碘使能自由基脱羧烯基化反应，并分离出一种新型的苯并恶唑醇-乙烯基羧酸反应中间体。这个C（sp 3）C（sp 2）偶联反应会生成含有各种敏感官能团的芳基和酰基取代的烯烃。优异的化学选择性，稳定的反应物和中性的水性反应条件表明了未来生物分子的应用。
• Asymmetric Synthesis of Aliphatic α-Amino and γ-Hydroxy α-Amino Acids and Introduction of a Template for Crystallization-Induced Asymmetric Transformation
  作者：Andrej Kolarovič、Pavol Jakubec、Dušan Berkeš、František Považanec

  DOI：10.1055/s-2006-950319

  日期：2006.12

  The asymmetric synthesis of aliphatic α-amino and γ-hy]droxy α-amino acids is described. The key step is an aza-Michael addition controlled by crystallization-induced asymmetric transformation (CIAT), affording excellent diastereomeric ratios (dr ≥96:4). Consecutive deoxygenation or stereoselective reduction (dr 99:1) furnish various α-amino and γ-hydroxy α-amino acids, respectively.

  描述了脂肪族α-氨基和γ-羟基α-氨基酸的不对称合成。关键步骤是由结晶诱导的不对称转变 (CIAT) 控制的 aza-Michael 加成，提供出色的非对映异构比 (dr ≥96:4)。连续脱氧或立体选择性还原 (dr 99:1) 分别提供各种 α-氨基和 γ-羟基 α-氨基酸。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME
  申请人：Kandula Mahesh

  公开号：US20150080345A1

  公开（公告）日：2015-03-19

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. such compositions may be used to treatment of fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glucose tolerance, or insulin resistance, high blood pressure, central obesity (also known as visceral, male-pattern or apple-shaped adiposity), overweight with fat deposits mainly around the waist, decreased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver (especially in concurrent obesity) progressing to NAFLD, polycystic ovarian syndrome (in women), hypophosphatemia, renal diseases, albuminuria, end stage renal disease, and acanthosis nigricans.

  本发明涉及化学式I和化学式II的化合物或其药学上可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括化学式I或化学式II化合物的有效量的药物组合物，以及用于治疗、预防或调节代谢综合征的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂的制剂。这些组合物可以用于治疗空腹高血糖、2型糖尿病、空腹血糖受损、糖耐量受损或胰岛素抵抗、高血压、中心性肥胖（也称为内脏、男性型或苹果形脂肪）、腰部脂肪沉积较多的超重、HDL胆固醇降低、甘油三酯升高、高尿酸血症、脂肪肝（尤其是伴有肥胖的进展到NAFLD）、多囊卵巢综合征（女性）、低磷血症、肾脏疾病、蛋白尿、晚期肾脏疾病和棕色糠疹。